Novo Nordisk A/S reported a 10% increase in sales to DKK 309.1 billion for 2025, driven largely by a 26% rise in obesity care sales; however, operating profit saw a slight decline due to transformation costs. Notably, the FDA approved the oral Wegovy® for obesity on December 22, 2025, with weekly prescriptions reaching about 50,000 by January 2026.